Stock Events

Stock Events

Search...

Biomm.

R$8.95

2

-R$0.15-1.65% Thursday 20:06

Statistics

Day High

9.14

Day Low

8.9

52W High

21.2

52W Low

4.04

Volume

64,600

Avg. Volume

89,184

Mkt Cap

499.92M

P/E Ratio

-

Dividend Yield

-

Dividend

-

People Also Follow

This list is based on the watchlists of people on Stock Events who follow BIOM3.SA. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.

Pfizer is a global pharmaceutical company that competes in the biopharmaceutical market, similar to Biomm, particularly in the development and distribution of vaccines and advanced biologic therapies.

Merck is a leading healthcare company that develops innovative pharmaceutical products, including biologic therapies, which directly competes with Biomm's product offerings.

Novartis is a multinational pharmaceutical company that produces a range of biopharmaceuticals, competing with Biomm in areas such as biosimilars and generic drugs.

GlaxoSmithKline focuses on the research and development of pharmaceuticals and vaccines, including biologics, which pits it against Biomm in the biopharmaceutical sector.

Sanofi operates globally in the pharmaceutical industry, producing similar biologic treatments and competing in the same therapeutic areas as Biomm.

Bristol-Myers Squibb

Bristol-Myers Squibb is involved in the discovery, development, and delivery of biopharmaceuticals, with a focus on innovative therapies that overlap with Biomm's market.

AbbVie is known for its significant biopharmaceutical products, directly competing with Biomm in the development and commercialization of advanced therapies.

Amgen specializes in human therapeutics, with a strong emphasis on biologic drugs, making it a direct competitor to Biomm in the biotech industry.

Roche Holding AG engages in the pharmaceutical and diagnostics business, competing with Biomm in the biopharmaceutical and biosimilar sectors.

Johnson & Johnson

Johnson & Johnson operates in various healthcare sectors, including pharmaceuticals where it develops biologics and other drugs that compete with Biomm's products.

About

Biomm S.A. operates as a biotechnology company in Brazil. It offers AFREZZA, a human insulin inhalation powder; GHEMAXAN, an enoxaparina sodica; GLARGILIN, a glargine insulin; WOSULIN R, a human insulin; WOSULIN N, isphane insulin; HERZUMA, a trastuzumab; and CANETA LIFEPEN G PARA APLICACAO DE INSULINA. The company was founded in 2001 and is headquartered in Nova Lima, Brazil.

Show more...

CEO

Mr. Heraldo Marchezini

Employees

148

Country

Brazil

ISIN

BRBIOMACNOR2

Listings